Search
Gadopiclenol
go.drugbank.com/drugs/DB17084ApprovedInvestigationalGadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … [L43817] In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues
Rocuronium
go.drugbank.com/drugs/DB00728ApprovedInvestigationalRocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. … [Sugammadex] is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
Products: Rocuroniumbromid Aguettant 10 mg/ml Injektionslösung in einer FertigspritzeRifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawnThe parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. … [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709]
Iobitridol
go.drugbank.com/drugs/DB12407ApprovedWithdrawnIobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.
Categories: Compounds used in a research, industrial, or household settingValoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.
Categories: Complex MixturesTucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.
Pegzilarginase
go.drugbank.com/drugs/DB14780ApprovedPegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.
SGS-742
go.drugbank.com/drugs/DB05010InvestigationalSGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
Categories: Compounds used in a research, industrial, or household settingSynonyms: (3-Aminopropyl)(n-butyl)phosphinic acidDamoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigationalin patients diagnosed with Haemophilia A. … [L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609]